Related Experiment Video
Updated: Jun 14, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Applying community-based participatory research principles and approaches in clinical trials: forging a new model for
Sarena D Seifer1, Margo Michaels, Stacy Collins
1Community-Campus Partnerships for Health, USA.
Abstract:
Although an estimated 20% of adult cancer patients are medically eligible for a cancer treatment clinical trial (CCT), adult trial participation in the U.S. remains under 3%.- Participation rates are even lower among ethnic and racial minorities and the medically underserved, who tend to have higher cancer mortality rates than the population as a whole.- Given persistent cancer health disparities in these populations, cancer clinical trial participation is increasingly an issue of social justice. Community-based participatory research (CBPR) approaches have been repeatedly recommended as a key strategy for increasing and diversifying cancer clinical trial participation and enhancing their relevance and quality. In 2006, Community-Campus Partnership for Health (CCPH) and the Education Network to Advance Cancer Clinical Trials (ENACCT) received funding from the Agency for Healthcare Research and Quality and the National Cancer Institute (NCI), along with industry and nonprofit partners, to develop the first set of national recommendations to employ CBPR approaches in multisite, phase III cancer clinical trials. The Communities as Partners in Cancer Clinical Trials: Changing Research, Practice and Policy final report, developed through a national advisory committee, two stakeholder meetings and a public vetting process, makes more than fifty detailed recommendations to engage communities in specific and meaningful ways throughout the cancer clinical trial process.1 The report is the first to provide specific guidance as to how and why clinical trials should involve communities affected by cancer-from trial design to implementation to dissemination of results. This paper describes the background and rationale for the initiative, the process used to develop and disseminate the report, and the challenges and opportunities for implementing the report's community-based approaches to cancer clinical research.
Insights
Community-based participatory research (CBPR) can increase cancer clinical trial (CCT) participation, especially among underserved groups. This initiative developed national recommendations for engaging communities in cancer clinical trials from design to results dissemination.
Area of Science:
- Oncology
- Public Health
- Health Disparities
Background:
- Adult cancer clinical trial (CCT) participation in the U.S. is below 3%, despite 20% eligibility.
- Participation is significantly lower among ethnic/racial minorities and underserved populations, exacerbating cancer mortality disparities.
- Community-based participatory research (CBPR) is recommended to improve CCT participation, relevance, and quality.
Purpose of the Study:
- To develop national recommendations for employing CBPR in multisite, phase III cancer clinical trials.
- To provide guidance on engaging communities throughout the cancer clinical trial process.
Main Methods:
- A national advisory committee, stakeholder meetings, and public vetting were used to develop recommendations.
- The initiative was funded by AHRQ and NCI, with industry and nonprofit partners.
- The process resulted in the "Communities as Partners in Cancer Clinical Trials" report.
Main Results:
- Over fifty detailed recommendations were made for community engagement in CCTs.
- Guidance covers community involvement from trial design to results dissemination.
- The report is the first to offer specific strategies for community involvement in cancer clinical research.
Conclusions:
- Implementing CBPR approaches is crucial for increasing and diversifying CCT participation.
- CBPR enhances the relevance and quality of cancer clinical trials.
- Addressing challenges and opportunities in CBPR implementation is key for advancing cancer research equity.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Treatment Resistent Cancers
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

